MHF TOP PICKS FOR November
Every month, we at the Mueller Health Foundation like to showcase interesting news and updates in the field of tuberculosis (TB). Below are our top 3 picks for November:
- AI-Driven Pharmacometrics Has the Potential to Transform Tuberculosis Treatment
A recent study highlights how the integration of artificial intelligence with pharmacometric modeling is poised to revolutionize the treatment of TB and Malaria in Africa. Traditional “one-size-fits-all” dosing regimens often fail to account for individual variability in drug absorption, metabolism, pathogen behavior, and host factors, leading to sub-optimal outcomes and increased risk of drug resistance. The new approach leverages machine-learning algorithms trained on extensive African clinical and biological datasets, combined with mechanistic pharmacokinetic/pharmacodynamic models, to predict patient responses and tailor dosing accordingly. By simulating many dosing strategies in silico, the hybrid platform aims to identify optimal regimens that maximize efficacy, minimize toxicity, and reduce resource burden in low-resource settings. Beyond TB, the framework holds promise for other infectious diseases, though its success depends on investments in data infrastructure, regulatory frameworks, and equitable access. To learn more, you can access the article here: https://www.nature.com/articles/s41467-025-64304-2
- Cytochrome bc1 Inhibitors Offer Hope for TB Treatment
Researchers are exploring a class of drugs called cytochrome bc1 inhibitors that could revolutionize TB treatment by disabling the bacterium’s essential respiratory enzyme complex. The enzyme, a key component of the pathogen’s energy-metabolism system, drives the production of ATP, a molecule that stores and supplies energy essential for cellular function. Disrupting this process effectively starves the bacteria of the energy it needs to survive.
DID YOU KNOW?
A new modeling study by Harvard T.H. Chan School of Public Health and Boston University School of Public Health projects that if U.S. bilateral health aid and contributions to the Global Fund to Fight AIDS, Tuberculosis and Malaria continue to be slashed, lowand middle-income countries could see significant increases in child TB cases and deaths:
- The study projects that between 2025 and 2034, Global Fund and U.S. funding cuts collectively could lead to an estimated 8.9 million additional childhood tuberculosis cases and over 1.5 million preventable child deaths worldwide.
- The modeling estimates that the more immediate scenario, meaning cuts in U.S. aid alone without Global Fund impact, would lead to about 2.5 million additional pediatric TB cases and 340,000 deaths in the same period.
- These figures are based on data from 130 countries, focusing specifically on children under 15 who are particularly vulnerable to TB, especially in regions with overlapping HIV burdens.
- The authors warn that decades of progress in reducing TB incidence and mortality could be reversed, undermining health systems and putting millions of children at heightened risk.
- Importantly, the study also finds that if funding were restored after just one year of interruption, up to 90% of the projected additional child deaths could be avoided.
While funding cuts threaten to undermine progress in childhood TB control, this moment also presents a critical opportunity to mobilize global solidarity, foster innovative partnerships, and renew investment in child health through sustainable, equitydriven financing mechanisms that can accelerate progress toward TB elimination.
https://pubmed.ncbi.nlm.nih.gov/40953585/